Fay Financial’s Post

CASE STUDY: Preventing "Over-improvements" - money you will likely not get back in future sale proceeds FOCUS: Saving initial cash outlay NOW - Increasing your financial returns later ASSIGNMENT: Determine the local market "max value" when vetting a properties potential worth - leveraging local market data & analytics

Join us this afternoon as we release our 2023 Full Year Financial results diving deeper into our financial performance and strategic outlook. Click the link below and click the notification bell to get notified: https://lnkd.in/dJhcPz77 #ForPeopleForBetter #KCBNiYetu

Discover how Wali Khan balances his full-time job with side hustles and investments. Gain insights into effective time management and financial growth strategies! Watch here: https://lnkd.in/dNAuD6AM

I bet you don't even know the definition of the biggest metric you should be analyzing... Here's how to truly understand what your revenue & true profit margin are Did a webinar on the 3 financial blindspots you never knew you had with Parker's Yacine Sibous & Milan Ray Full webinar in the comments!

Yesterday, Daré Bioscience, Inc. announced full year 2023 financial results, showing once again that we’ve built the premier company in women’s health with the broadest portfolio of potentially first-in-category product candidates. We made significant strides in 2023 to advance innovative therapies for women and position ourselves well for the milestones to come in 2024. In 2023 alone, we announced the first shipment of XACIATO™ in connection with its launch in the United States, had 15 interactions with the FDA across six product candidates / indications, commenced the pivotal Phase 3 study for our hormone-free monthly intravaginal contraceptive candidate Ovaprene, successfully completed the Phase 2b study of our investigational Sildenafil Cream product in female sexual arousal disorder and the DARE-PDM1 vaginal diclofenac for menstrual pain Phase 1 study, and received IND clearance for DARE-VVA1, our hormone-free treatment for sexual pain. I’m also excited about the increased attention that women’s health has received more broadly since the White House announced the first-ever initiative on women’s health research in November, an effort led by First Lady Dr. Jill Biden and the White House Gender Policy Council, which emphasized that to “achieve scientific breakthroughs and strengthen our ability to prevent, detect, and treat diseases, we have to be bold.” (Oh yes, we do, and we are – and personally, it’s rewarding to see that language given in English, “Daré” means “to be bold”!) I’ve also had the pleasure of attending in person both the ARPA-H announcement with Dr. Biden in Boston last month and the signing of the executive order at the White House just last week – all moments that remind me just how much we can accomplish by bringing focus and investment to the entire ecosystem to boldly innovate for women. Our achievements, coupled with these recent industry developments, underscore what a fantastic time it is to be working in women’s health, and the significant opportunity in this space. But most importantly, our achievements in 2023 demonstrate that our approach to accelerating clinical development works, and that our leading programs have disruptive potential in the conditions and populations they aim to treat. None of these successes would have been possible without the Daré team’s unwavering commitment to advancing innovation for women’s health, which continues to drive our progress. I look forward to building on this momentum as we continue to accelerate therapies that increase options, improve outcomes, and offer convenience for women’s most persistent unmet needs. Learn more about our financial results and company update here: https://bit.ly/3VwTx33

How do you measure success?

📣 Our 2024 Q1 financial results are in. We remain on track to achieve the midpoint of our 2024 financial guidance. Read more: https://oneg.as/3UzbN9E

Here are some key facts about reporting:

2024 Half Year Financial Results Join us for the announcement of the 2024 Half Year Results

How do we know this for sure? With our top-notch, data-driven valuations. That’s how. Learn more at